Physician profile
Jay Thomas Pohl
NPI 1235123407
$14,138.61
in general payments reported to CMS, 2019-2025
51 companies · $2,377 in 2025
The $2,377 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,611 · 2020: $1,506 · 2021: $1,761 · 2022: $1,845 · 2023: $2,435 · 2024: $2,604 · 2025: $2,377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,416.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,415.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,269.72 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,485.41 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $1,469.05 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $1,075.66 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $717.77 | 2019-2025 | |
| Glaxosmithkline, LLC. | $674.97 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $530.34 | 2019-2024 | Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $508.81 | 2019-2025 | Jardiance, Synjardy |
| Merck Sharp & Dohme LLC | $434.66 | 2019-2025 | Gardasil 9, Vaxelis, Capvaxive |
| Abbott Laboratories | $427.94 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Exact Sciences Corporation | $370.23 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $357.54 | 2019-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $332.69 | 2024-2025 | Caplyta |
| Lundbeck LLC | $317.09 | 2023-2025 | Vyepti, Rexulti |
| Novartis Pharmaceuticals Corporation | $282.00 | 2021-2025 |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $270.03 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $266.45 | 2021-2025 | Xifaxan, Trulance |
| Sanofi-Aventis U.S. LLC | $235.11 | 2019-2025 | |
| Antares Pharma, INC. | $219.69 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Corcept Therapeutics | $170.32 | 2024-2025 | Korlym |
| Janssen Pharmaceuticals, INC | $157.25 | 2019-2021 | |
| Dexcom, INC. | $124.66 | 2024-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Amarin Pharma, INC. | $123.27 | 2019-2021 | |
| Corium, LLC | $113.38 | 2022-2023 | Azstarys |
| Idorsia Pharmaceuticals US INC | $108.29 | 2022-2024 | Quviviq |
| Mylan Specialty L.P. | $103.29 | 2021-2024 | Yupelri |
| Axsome Therapeutics, INC. | $89.80 | 2024-2025 | Symbravo, Auvelity |
| Allergan, INC. | $86.11 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $78.38 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $72.36 | 2019 | |
| Adlon Therapeutics L.P. | $61.59 | 2019-2021 | |
| Astellas Pharma US INC | $53.33 | 2019-2021 | |
| Sanofi Pasteur INC. | $52.90 | 2023-2025 | |
| Halozyme INC | $47.46 | 2023 | |
| Vanda Pharmaceuticals INC. | $47.41 | 2025 | Fanapt |
| Eisai INC. | $43.44 | 2020-2021 | |
| Ironshore Pharmaceuticals INC. | $41.77 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $38.67 | 2025 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $35.12 | 2022-2023 | Seglentis, Livalo |
| Sumitomo Pharma America, INC. | $32.55 | 2023-2024 | Gemtesa |
| Currax Pharmaceuticals LLC | $30.01 | 2021-2024 | Contrave |
| Phathom Pharmaceuticals, INC. | $29.87 | 2025 | Voquezna |
| Inspire Medical Systems, INC. | $23.17 | 2025 | Inspire |
| Tris Pharma INC | $21.89 | 2024 | Dyanavel Xr |
| Melinta Therapeutics, LLC | $16.07 | 2021 | |
| Supernus Pharmaceuticals, INC. | $15.84 | 2021 | Xyosted, Tlando |
| Philips North America LLC | $15.50 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Genentech USA, INC. | $15.43 | 2020 | |
| Vertex Pharmaceuticals Incorporated | $15.24 | 2025 | |
| Optinose US, INC. | $14.73 | 2019 | |
| Esperion Therapeutics, INC. | $14.35 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Pohl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.